Dashboard
Manage Tickers

NVS NOVARTIS AG

NYSE novartis.com


$ 129.96 $ 0.00 (0 %)    

Friday, 17-Oct-2025 04:21:43 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 591.32 $ 0.00 (0 %)
DIA $ 455.11 $ 0.00 (0 %)
SPY $ 652.50 $ 0.00 (0 %)
TLT $ 91.47 $ 0.00 (0 %)
GLD $ 399.75 $ 0.00 (0 %)
$ 130.77
$ 129.88
$ 129.54 x 600
$ 130.02 x 100
-- - --
$ 92.72 - $ 133.55
1,169,096
na
258.28B
$ 0.48
$ 21.63
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

small-cap-biotech-climb-bios-lead-drug-candidate-has-larger-long-term-opportunity
Small-Cap Biotech Climb Bio's Lead Drug Ca...
10/16/2025 17:40:28

William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therap...

novartis-strengthens-kidney-disease-pipeline-with-promising-data
Novartis Strengthens Kidney Disease Pipeli...
10/16/2025 14:50:29

Novartis' Fabhalta showed significant efficacy and safety in a Phase 3 IgA nephropathy study, supporting regulatory filings...

vor-bios-collaborator-delivers-positive-results-for-telitacicept-in-autoimmune-disorder-that-impacts-tears
Vor Bio's Collaborator Delivers Positive R...
10/14/2025 16:22:03

Telitacicept showed strong efficacy and safety in a 48-week Phase 3 trial for Sjögren's disease, meeting all primary and se...

novartis-receives-fda-approval-for-rhapsido-the-only-oral-targeted-btki-treatment-for-chronic-spontaneous-urticaria
Novartis Receives FDA Approval For Rhapsid...
09/30/2025 20:44:16

https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-rhapsido-remibrutinib-only-oral-targeted-btki-treat...

pharmas-direct-to-patient-wave-hits-novartis-next
Pharma's Direct-To-Patient Wave Hits Novar...
09/29/2025 18:01:07

The Pharmaceutical Research and Manufacturers of America (PhRMA) outlined initiatives to bolster U.S. manufacturing, ease patie...

novartis-to-launch-direct-to-patient-platform-for-cosentyx-in-us-with-55-discount-starting-november-1-2025
Novartis To Launch Direct-To-Patient Platf...
09/29/2025 13:35:29

 Select units of Cosentyx to be made available at 55% discount off list price on direct-to-patient (DTP) platform beginning Nov...

trumps-100-pharmaceutical-tariff-the-270-billion-manufacturing-war-that-could-reshape-your-medicine-cabinet
Trump's 100% Pharmaceutical Tariff: The $2...
09/26/2025 12:01:51

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creatin...

novartis-expects-no-impact-from-100-us-tariff
Novartis Expects No Impact From 100% US Ta...
09/26/2025 10:05:32

-Reuters

Core News & Articles
Reported Earlier, President Trump Starting...
09/26/2025 05:43:23

https://truthsocial.com/@realDonaldTrump/posts/115267512131958759 

trumps-new-tariff-barrage-targets-drugs-trucks-cabinets-president-says-move-will-protect-manufacturers-from-unfair-outside-competition
Trump's New Tariff Barrage Targets Drugs, ...
09/26/2025 02:41:29

President Donald Trump announced a barrage of new tariffs on Thursday, aimed at pharmaceuticals, heavy trucks and home furnishi...

eli-lilly-stock-is-trading-down-thursday-whats-behind-the-move
Eli Lilly Stock Is Trading Down Thursday: ...
09/25/2025 19:26:55

Eli Lilly and Company (NYSE: LLY) shares are trading lower after the company ended a mid-stage study of its experimental drug b...

eli-lilly-ends-bimagrumab-obesity-study-weeks-after-launch
Eli Lilly Ends Bimagrumab Obesity Study We...
09/25/2025 15:23:56

On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients w...

novartis-abbvie-face-legal-defeat-over-340b-contract-pharmacies
Novartis, AbbVie Face Legal Defeat Over 34...
09/24/2025 17:52:04

A judge upholds Maine's contract pharmacy law, rejecting drugmakers' claims that it conflicts with federal rules govern...

scholar-rocks-spinal-muscular-atrophy-drug-faces-fda-delay-over-catalent-indiana-inspection
Scholar Rock's Spinal Muscular Atrophy Dru...
09/23/2025 15:32:30

FDA cites Catalent Indiana issues in Scholar Rock's SMA drug review; European approval decision expected in 2026, with Germ...

roche-targets-top-spot-in-weight-loss-drug-market
Roche Targets Top Spot In Weight Loss Drug...
09/22/2025 18:04:15

Roche advances weight loss drug CT-388 to Phase III, boosts pipeline with major acquisitions.

novartis-builds-us-drug-reserves-against-potential-tariffs
Novartis Builds US Drug Reserves Against P...
09/22/2025 15:00:09

Novartis bolsters U.S. drug reserves and plans $23 billion in investments as CEO Vas Narasimhan addresses tariff risks and trad...

monte-rosa-novartis-use-ai-powered-engine-to-advance-immune-disease-treatments
Monte Rosa, Novartis Use AI-Powered Engine...
09/15/2025 15:29:40

Monte Rosa's stock jumps as it partners with Novartis to develop degraders for immune diseases, with up to $5.7 billion in ...

this-applied-materials-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-friday
This Applied Materials Analyst Is No Longe...
09/12/2025 12:44:20

goldman-sachs-downgrades-novartis-to-sell-lowers-price-target-to-118
Goldman Sachs Downgrades Novartis to Sell,...
09/12/2025 09:11:49

Goldman Sachs analyst James Quigley downgrades Novartis (NYSE:NVS) from Neutral to Sell and lowers the price target from $11...

trumps-biotech-playbook-ignites-350-billion-investment-blitz
Trump's Biotech Playbook Ignites $350 Bill...
09/09/2025 14:41:15

Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue opportunities. Investors c...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION